Novel OSDrC® Optimized Dosing Technology Expands Drug Release Options

Catalent and Sanwa Announce Exclusive License For OSDrC® Technology, Bringing New Modified Release Delivery Technology to the RX and OTC Global Market

Somerset, NJ, and Swindon, UK, July 14, 2011 – Catalent Pharma Solutions, a leading global drug delivery technology company and Sanwa Kagaku Kenkyusho Co., Ltd, a leading Japanese pharmaceutical and health care company, have entered into an exclusive agreement to bring Sanwa’s innovative drug delivery tableting technology to global markets.  This novel technology will be marketed by Catalent in all markets outside of Japan, Korea, China (Hong Kong), and Taiwan.  OSDrC® is a fully developed optimized dose delivery technology and has already been commercially proven by Sanwa in Japan.  Catalent will now utilize its global footprint, leading modified release delivery expertise, and integrated manufacturing know-how to bring OSDrC® to the global market.  This technology enables significant improvements to therapeutic and drug delivery release profiles.  It is anticipated that Catalent will commence customer product development trials at its Winchester, Kentucky facility in January, 2012.

About OSDrC® technology

OSDrC® optimized dose delivery technology enables the design of single or multi-core tablets, with a practically endless variety of core numbers, shapes, sizes, and placement within the tablet.  This flexible-core capability offers the broadest available range of controlled release designs for drug formulators, providing the potential for optimal dosing, therapeutic product profiles, and plasma release profiles to meet patient needs in a high quality, one step manufacturing process.

OSDrC® technology can produce pulsatile tablets, bi-layer tablets, multi-core tablets, dividable tablets, delayed release tablets, and direct compression orally dissolving tablets with better quality and release control design than standard tableting technologies.

This technology expands Catalent’s capabilities in designing pulsatile targeted drug delivery, immediate and extended release combination tablets, and combination product tablets containing multiple active drugs.  OSDrC®, in addition to other recent technology advances at its Winchester, Kentucky and Schorndorf, Germany facilities, is part of an overall growth initiative for Catalent to expand its leading modified release technology capabilities.

Dr. Ian Muir, President of Catalent’s Modified Release Technologies business, stated, “We are excited to partner with Sanwa as we continue to expand and innovate our modified release technology solutions and manufacturing capabilities.  The addition of OSDrC® optimized dose delivery technology will enhance Catalent’s ability to solve our customer’s controlled release formulation challenges - by providing the broadest and highest quality range of drug delivery technologies and scientific expertise in the industry.  It is a perfect fit with our existing controlled release, Zydis® and Lyopan® fast dissolve, and Stick Pack modified release technology platform to enhance our ability to bring more products and better treatments to the market.”

Mr. Kazuo Yamamoto, President of Sanwa stated, “OSDrC® technology already has an existing application in the Japanese market.  Catalent’s global presence, modified release technology scientific expertise, and integrated manufacturing and packaging services make them the ideal partner for Sanwa as we make this innovative technology available for global customers to improve their products.”
Michael J. Valazza R.Ph., Global Vice President of Catalent’s Modified Release Technologies business, will be presenting this new technology at the 38th Annual Controlled Release Society Conference on Sunday, July 31 from 8:30 – 9:30 am at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

If you would like to conduct any follow-up interviews or learn more about OSDrC® technology, please contact Patricia McGee at .

To learn more about Catalent’s modified release technologies, please visit .

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 8,000 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ.

more products. better treatments. reliably supplied.™
About Sanwa

Sanwa Kagaku Kenkyusho Co., Ltd is a leading Japanese health care company.  Their business is concentrated in research and development, manufacture, and sales of drugs, diagnostics, medical foods, health care products and contract manufacturing of drugs.  Sanwa is headquartered in Nagoya, Japan, with fiscal year 2010 annual revenue of 68.3 billion yen.

OSDrC® is a registered trademark of Sanwa Kagaku Kenkyusho Co., Ltd
Zydis® is a registered trademark of Catalent Pharma Solutions
Lyopan® is a registered trademark of Pantec AG